Recovery after ICL surgery

• First 24-48 hours: Vision is often noticeably clearer quickly, but may be hazy or fluctuate. Mild scratchiness, tearing, light sensitivity, redness, and glare/halos are common. A next-day eye-pressure check is important.
• First week: Most people return to desk work and normal light activity within a few days, depending on their surgeon’s advice. Use prescribed antibiotic and anti-inflammatory drops.
• About 1-2 weeks: Vision and comfort commonly stabilize substantially. Avoid rubbing the eyes, swimming/hot tubs, contact sports, dusty environments, and eye makeup until your surgeon clears them.
• Several weeks to months: Night vision effects and small prescription fluctuations can continue improving. Follow-up visits are needed to check lens position, “vault” or spacing from the natural lens, corneal health, and eye pressure.

Possible side effects and complications

• Blurry or fluctuating vision
• Redness, irritation, tearing, dry-eye sensation, or light sensitivity
• Halos, glare, starbursts, reduced night-vision quality, and occasionally double vision
• Mild inflammation in the eye

• Raised intraocular pressure, sometimes early after surgery. This can cause headache, eye pain, nausea, halos, or blurred vision and needs prompt assessment.
• Lens rotation or suboptimal position, especially with toric ICLs, which may require repositioning or exchange.
• Cataract formation or clouding of the natural lens, particularly a longer-term concern.
• Corneal endothelial-cell loss or corneal swelling.
• Pigment dispersion, inflammation, or secondary glaucoma.
• Retinal tear/detachment, especially relevant for people with high myopia.
• Infection inside the eye, bleeding, persistent loss of best-corrected vision, or need for lens removal/exchange. These are uncommon but can threaten sight.

Best available estimates

• Sphere: -7.50 D myopia
• Cylinder: -2.25 D astigmatism
• Spherical equivalent: approximately -8.63 D
  Calculation: -7.50 + half of -2.25 = -8.625 D.

1. Anterior chamber depth: commonly at least 3.0 mm for FDA-labeled use.
2. Endothelial cell count: enough corneal endothelial reserve for your age.
3. Sulcus anatomy and expected ICL vault: measured with anterior-segment imaging.
4. Retinal examination: especially important with moderate-to-high myopia.
5. Corneal topography/tomography: checks for keratoconus or irregular astigmatism.
6. Prescription stability: generally no more than 0.50 D change over the prior year.

1. Cataract risk
   • Ask: “What is my expected lens vault, and does my anatomy increase the risk of the ICL touching my natural lens over time?”
   • A cataract may require ICL removal and cataract surgery. The EVO central port appears to reduce this risk compared with older ICL models, but it is not zero.
2. Eye-pressure rise and glaucoma
   • Ask about your baseline eye pressure, angle anatomy, pigment-dispersion risk, and the plan for pressure checks after surgery and long term.
   • Acute pressure spikes are mainly an early issue, but chronic pressure elevation or glaucoma, though uncommon, is a longer-term concern. The FDA EVO study recorded glaucoma in about 0.3% of eyes during its study follow-up, which is not a lifetime estimate.
3. Corneal endothelial-cell loss
   • These are cells lining the inside of the cornea and they do not regenerate.
   • Ask: “What is my endothelial cell count for my age, what minimum is acceptable, and how often will you repeat the count after surgery?”
   • The FDA labeling includes endothelial-cell loss as a risk. A 2024 meta-analysis found average loss around 1.75% at one year and 3.84% at about 21 months after V4c ICL surgery, although individual results vary.
4. Toric-lens rotation
   • This is particularly relevant to your -2.25 D astigmatism. If the lens rotates, astigmatism correction drops and vision can blur or ghost.
   • Ask: “What is your rate of toric ICL rotation and reoperation, and at what degree of rotation would you reposition it?”
   • It can require a second procedure to rotate or exchange the lens.
5. Lens sizing, position, and need for removal/exchange
   • An ICL that sits too close to the natural lens, iris, or angle can cause problems. An excessively high or low vault may lead to monitoring, repositioning, or exchange.
   • Ask what measurements will be used for sizing, such as anterior-segment OCT or ultrasound biomicroscopy, and whether the practice audits its lens exchange rate.
6. Residual prescription and future enhancement
   • ICL does not guarantee perfect unaided vision. You may retain some sphere/cylinder, and your prescription can change over time.
   • Ask: “What is the chance I will still need glasses, and is a laser enhancement possible if needed?”
   • You will also eventually develop presbyopia, so reading glasses are likely in your 40s even if distance vision is excellent.
7. Night-vision quality
   • Ask about glare, halos, starbursts, contrast sensitivity, pupil size in dim light, and night driving.
   • Older ICL FDA data reported worsening of halos/glare in roughly 10% of patients at 3 years, but those data came from an earlier lens generation and are not a direct prediction for EVO ICL.
8. Retinal tear or detachment
   • Your myopia itself raises retinal risk, independently of ICL. ICL surgery does not remove that underlying risk.
   • Ask for a dilated retinal examination before surgery, whether you have lattice degeneration or retinal holes, and what symptoms require urgent review: flashes, sudden new floaters, or a curtain/shadow.
9. Long-term follow-up plan
   • Ask exactly which tests will be repeated and how often: visual acuity/refraction, eye pressure, vault assessment, endothelial-cell count, and dilated retinal examination.
   • Ask what happens if you relocate, miss follow-up, develop cataract, or later need cataract surgery.
10. Surgeon-specific outcomes

• Ask for their own rates of infection, ICL repositioning/exchange/removal, significant pressure rise, cataract, and toric rotation. Their outcomes are more informative for your decision than a brochure average.

• Blurred or cloudy vision from corneal swelling, called corneal edema
• Vision worse on waking, which may improve later in the day as the cornea dries slightly
• Glare, halos, and reduced contrast, especially at night
• Light sensitivity, tearing, eye redness, or a foreign-body sensation
• Painful surface blisters in advanced corneal edema. These can rupture and raise infection/scarring risk.
• Permanent corneal scarring and reduced vision if edema is prolonged
• Need for corneal endothelial transplant surgery, such as DMEK or DSAEK, if the cornea can no longer remain clear

1. What is my baseline endothelial cell density in each eye?
2. Is it acceptable for my age under the ICL manufacturer criteria?
3. Is there any sign of Fuchs endothelial dystrophy, guttae, or other corneal disease?
4. How often will you repeat specular microscopy and corneal thickness measurements after surgery?
5. What degree or rate of cell loss would make you recommend ICL removal or closer monitoring?

Approximate normal central endothelial cell density by age

What number is concerning?

• Above 2,500 cells/mm²: usually a comfortable reserve in a young adult, assuming normal cell appearance and no corneal disease.
• 2,000-2,500 cells/mm²: may still be normal, particularly with increasing age, but it needs interpretation in context.
• 1,500-2,000 cells/mm²: reduced reserve. Intraocular surgery requires more caution and individualized assessment.
• Below about 1,000-1,500 cells/mm²: risk of corneal decompensation rises, particularly after intraocular surgery.
• Below about 500 cells/mm²: the cornea often cannot maintain clarity, so edema and impaired vision may develop.

• Your endothelial cell density in each eye
• Cell shape and variation in cell size, often reported as hexagonality and coefficient of variation
• Corneal thickness and whether it is stable
• Whether there are guttae or signs of Fuchs endothelial dystrophy
• The manufacturer age-specific minimum required for the particular ICL model being proposed

FDA minimum ECD for EVO ICL

What would make an ICL unsafe or concerning?

• Your ECD is below the relevant table minimum for your age and true ACD.
• The count is technically acceptable but you have guttae, Fuchs endothelial dystrophy, abnormal cell shape/size, or unexplained corneal thickening.
• Repeat tests show a concerning downward trend before surgery.

• Progressive loss faster than expected on repeat specular microscopy
• A count trending toward a level that gives inadequate lifetime reserve, especially toward 1,000-1,500 cells/mm²
• Corneal edema, persistent morning blur, increasing corneal thickness, or reduced vision attributable to endothelial dysfunction
• An ICL position, vault, pressure problem, inflammation, or other issue that may be contributing

“Based on my age, true ACD, and endothelial cell count in each eye, am I above the FDA minimum with a comfortable safety margin? What repeat ECD result or rate of loss would make you recommend closer monitoring, ICL exchange, or removal?”